Clinical Trial: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Crohn's Disease
Study Type: INTERVENTIONAL
Official Title: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease
Brief Summary:
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease.Study periods for the intervention-specific appendix (ISA) will be as follows:A 12-week induction periodA maintenance period from Week 12 to Week 52, andA safety follow-up period up to 16 weeks.The study…
Read more